The Clinical PD Biomarkers Program is responsible for identification of biomarkers of response to new targeted agents entering clinical trials in the Developmental Therapeutics Program of the National Cancer Institute. The scope of work includes assay design, development, validation, fitness for purpose testing, transfer of assays to clinical laboratories, and clinical specimen analysis when required. The program facilitates mechanistic and performance analysis of putative anti-cancer agents, diagnostic tests, and therapeutic interventions to clinical applications, including distinct molecular signatures for cancer, refined molecular assays, and state-of-the-art imaging techniques that are too high-risk for industry or academia to pursue. The program operates a number of advanced, specialized instrumentation for image analysis of tumor biopsies, circulating tumor cells, and activated Tcells for measuring drug effects in patients enrolled in clinical trials.

Perform data analysis and reporting of results from clinical specimen biopsies to the NCI

BASIC QUALIFICATIONS

Possession of a Doctoral degree from an accredited university according to the Council for Higher Education Accreditation. (Additional qualifying experience may be substituted for the required education). Foreign degrees must be evaluated for U.S. equivalency

Design of cell-based assays to test mechanism of action of candidate compounds

Ability to master novel technologies and instrumentation in response to changes in project priorities or breakthrough technological innovations; hands-on instrumentation work is required for this position

Ability to communicate with program lead researchers in a demanding scientific environment through preparation of formal reports is essential

Ability to maintain precise records

Must be able to obtain and maintain a security clearance

PREFERRED QUALIFICATIONS

Experience in isolation and characterization of individual target cells